Jump to content

DPI-3290

From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
DPI-3290
Identifiers
  • 3-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N-(3-fluorophenyl)-N-methylbenzamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC30H34FN3O2
Molar mass487.619 g·mol−1
3D model (JSmol)
  • C[C@H]1CN([C@@H](CN1[C@@H](C2=CC(=CC=C2)O)C3=CC=CC(=C3)C(=O)N(C)C4=CC(=CC=C4)F)C)CC=C
  • InChI=1S/C30H34FN3O2/c1-5-15-33-19-22(3)34(20-21(33)2)29(24-10-7-14-28(35)17-24)23-9-6-11-25(16-23)30(36)32(4)27-13-8-12-26(31)18-27/h5-14,16-18,21-22,29,35H,1,15,19-20H2,2-4H3/t21-,22+,29-/m1/s1 ☒N
  • Key:LZXRQLIIMYJZDA-UETOGOEVSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

DPI-3290 was discovered by scientists at Burroughs Wellcome and licensed to Delta Pharmaceutical [1] and is a drug that is used in scientific research. It is a potent analgesic drug,[2] which produces little respiratory depression.[3]

DPI-3290 acts as an agonist at both μ- and δ-opioid receptor, with an IC50 of 6.2nM at μ and 1.0nM at δ.[4]

See also

References

  1. ^ US Patent 5552404 - Opioid compounds and methods for using same
  2. ^ Gengo PJ, Pettit HO, O'Neill SJ, Wei K, McNutt R, Bishop MJ, Chang KJ (December 2003). "DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A mixed opioid agonist with potent antinociceptive activity". The Journal of Pharmacology and Experimental Therapeutics. 307 (3): 1221–6. doi:10.1124/jpet.103.054361. PMID 14534368. S2CID 93569860.
  3. ^ Gengo PJ, Pettit HO, O'Neill SJ, Su YF, McNutt R, Chang KJ (December 2003). "DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. II. A mixed opioid agonist with potent antinociceptive activity and limited effects on respiratory function". The Journal of Pharmacology and Experimental Therapeutics. 307 (3): 1227–33. doi:10.1124/jpet.103.054429. PMID 14534367. S2CID 45159720.
  4. ^ Ananthan S (March 2006). "Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics". The AAPS Journal. 8 (1): E118-25. doi:10.1208/aapsj080114. PMC 2751430. PMID 16584118.